Prediction of the Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Based on Short-Term Changes in Multiple Risk Markers

Sok Cin Tye, Sieta T. de Vries, Christoph Wanner, Petra Denig, Hiddo J. L. Heerspink

Open source

DOI
10.3389/fphar.2021.786706
Published
2022-01-25
Container
Frontiers in Pharmacology
Publisher
Frontiers Media SA
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fphar.2021.786706,
  title = {Prediction of the Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Based on Short-Term Changes in Multiple Risk Markers},
  author = {Sok Cin Tye and Sieta T. de Vries and Christoph Wanner and Petra Denig and Hiddo J. L. Heerspink},
  year = {2022},
  journal = {Frontiers in Pharmacology},
  doi = {10.3389/fphar.2021.786706},
  url = {https://doi.org/10.3389/fphar.2021.786706}
}

RIS

TY  - JOUR
TI  - Prediction of the Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Based on Short-Term Changes in Multiple Risk Markers
AU  - Sok Cin Tye
AU  - Sieta T. de Vries
AU  - Christoph Wanner
AU  - Petra Denig
AU  - Hiddo J. L. Heerspink
PY  - 2022
JO  - Frontiers in Pharmacology
DO  - 10.3389/fphar.2021.786706
UR  - https://doi.org/10.3389/fphar.2021.786706
ER  - 

APA

Tye, S. C., Vries, S. T. D., Wanner, C., Denig, P., & Heerspink, H. J. L. (2022). Prediction of the Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Based on Short-Term Changes in Multiple Risk Markers. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2021.786706

Source records